Provision of over-encapsulated Sitagliptin (Januvia), Pioglitazone (Actos) and Cangliflozin (Invokana) for a double-blind randomised clinical trial
key details
| Value | £500,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 1 Sept 2015 |
| Contract start | 22 Sept 2015 |
| Contract end | 31 Jul 2019 |
| Procedure | open |
| SME suitable | No |
| OCID | ocds-b5fd17-ac9489d2-adc8-11e6-9901-0019b9f3037b |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Tayside Pharmaceuticals | £528,571 | 13 Sept 2015 | active |
description
The University of Exeter is seeking a suitable and capable provider of investigational medicinal product for use by its Medical School as part of a diabetes clinical trial. The Unviersity of Exeter Medical School is undertaking a MRC-funded study aiming to develop a stratified approach in Type 2 diabetes that will result in more effective use of glucose lowering therapy. The Trimaster trial, sponsored by the Royal Devon & Exeter NHS Foundation Trust (RD&E FT) is a randomised double-blind Cross-Over trial of three standard diabetes therapies, a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in 600 patients with type 2 diabetes. It aims to directly test potential stratification by comparing a patient’s response (in terms of glycaemia, weight change, hypoglycaemia and patient reported outcomes) to these three glucose-lowering treatments.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 14 Aug 2015 | Award (award) | · | ocds-b5fd17-ac9489d2-adc8-11e6-9901-0019b9f3037b-71595-uoe-2015-042 |
more from UNIVERSITY OF EXETER
- Website Cloud hosting · £227,609 · 15 Oct 2024
- ORE Repository · £200,000 · 16 May 2024
- eTendering · £60,000 · 23 Feb 2024
- eMarketplace · £91,135 · 20 Sept 2023
- Student Engagement Platform · £60,000 · 15 Nov 2022
- TRAC Software · £132,000 · 7 Jul 2022
- Virtual Server Platform · £355,443 · 1 Apr 2022
- Teamviewer Software · £90,485 · 18 Mar 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.